Viiv Healthcare UK Limited
- Address
- 980 Great West Road
Sponsor Overview
Specializations
HIV-1 Treatment in Antiretroviral-Naïve Adults
Clinical research includes oral and long-acting antiretroviral therapy options for adults newly diagnosed with HIV, with attention to viral suppression, treatment initiation, and regimen selection in people who have not previously received therapy.
- Oral once-daily treatment regimens
- Long-acting injectable ART
- Viral suppression in treatment-naïve adults
Studies also examine comparative effectiveness between simplified dual-drug and standard multi-drug approaches in initial HIV-1 management.
Long-Acting and Switch-Based Maintenance Therapy
Research activity extends to maintaining virologic suppression after switching from established oral regimens to long-acting combinations, including injectable approaches for adults already living with controlled HIV infection.
- Switch strategies after suppression
- Two-monthly injectable combinations
- Durability of treatment response
This area includes assessment of treatment choice and preference in adults considering oral versus injectable maintenance options.
Heavily Treatment-Experienced and Drug-Resistant HIV
The sponsor supports studies in adults with limited treatment options due to multidrug-resistant HIV-1 or prior antiretroviral exposure, including settings where current regimens are failing or no longer fully effective.
- Drug-resistant HIV-1
- Heavily treatment-experienced populations
- Salvage and rescue treatment strategies
Research in this domain focuses on restoring antiviral control in people with complex treatment histories.
Novel Antiviral Agents and Regimen Innovation
Clinical work includes evaluation of new HIV therapies such as attachment inhibitors, capsid-targeting agents, and other oral compounds designed to expand treatment choices for both untreated and treatment-experienced adults.
- Attachment inhibitor-based regimens
- Capsid-directed antiviral candidates
- Oral regimen development
These studies are directed toward improving antiviral activity and broadening options for HIV-1 management.
Reservoir and Immune-Based HIV Research
Additional research interest includes the viral reservoir and the use of broadly neutralizing antibodies alongside integrase inhibitor-based therapy in adults living with HIV.
- Viral reservoir modulation
- Broadly neutralizing antibodies
- Combination approaches with integrase-based therapy
This area reflects interest in deeper virologic control beyond routine suppression.
Sponsored Trials
Data & Insights
This sponsor works with 12 molecules, of which 5 are not being studied by other sponsors.
This sponsor has worked with 133 sites across their trial portfolio.
Therapeutic Focus
- 1.Virus Diseases10 trials182 other sponsors
- 2.Immune System Diseases2 trials322 other sponsors
Partnered Research Centres
133 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- Carrer Del Doctor Joan Soler 1-3, 08243 Manresa
- Address
- Meibergdreef 9, 1105 AZ Amsterdam
- Address
- Avenida De Las Islas Baleares 3, 09006 Burgos
- Address
- 46 Rue Henri Huchard, 75877 Paris
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Viiv Healthcare UK Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.